Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no other study content or page functionality is affected.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure line and the previous Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check52 days agoChange DetectedPublications section updated to clarify that publications are provided voluntarily by the person entering information and relate to the study results. Revision tag updated to v3.3.2.SummaryDifference0.1%

- Check59 days agoChange DetectedThe government funding status notice on the page was removed; no changes to the study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedNo significant changes detected between the two screenshots; core study content, eligibility criteria, and participating locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check102 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing v3.1.0.SummaryDifference2%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.